Biblio
Export 796 results:
Author Title Type [ Year
Filters: First Letter Of Keyword is P [Clear All Filters]
“Course and Determinants of Anosognosia in Alzheimer's Disease: A 12-Month Follow-up.”, J Alzheimers Dis, vol. 51, no. 2, pp. 357-66, 2016.
, “Cycloheximide Treatment Causes a ZVAD-Sensitive Protease-Dependent Cleavage of Human Tau in Drosophila Cells.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1161-8, 2016.
, “Cycloheximide Treatment Causes a ZVAD-Sensitive Protease-Dependent Cleavage of Human Tau in Drosophila Cells.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1161-8, 2016.
, “Cycloheximide Treatment Causes a ZVAD-Sensitive Protease-Dependent Cleavage of Human Tau in Drosophila Cells.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1161-8, 2016.
, “Delusions in Patients with Alzheimer's Disease: A Multidimensional Approach.”, J Alzheimers Dis, vol. 51, no. 2, pp. 427-37, 2016.
, “Dementia Apraxia Test (DATE): A Brief Tool to Differentiate Behavioral Variant Frontotemporal Dementia from Alzheimer's Dementia Based on Apraxia Profiles.”, J Alzheimers Dis, vol. 49, no. 3, pp. 593-605, 2016.
, “Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 49, no. 3, pp. 743-54, 2016.
, “Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension.”, J Alzheimers Dis, vol. 49, no. 2, pp. 423-32, 2016.
, “Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension.”, J Alzheimers Dis, vol. 49, no. 2, pp. 423-32, 2016.
, “Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension.”, J Alzheimers Dis, vol. 49, no. 2, pp. 423-32, 2016.
, “Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 52, no. 1, pp. 17-24, 2016.
, “Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 52, no. 1, pp. 17-24, 2016.
, “Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 52, no. 1, pp. 17-24, 2016.
, “Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 97-106, 2016.
, “Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 97-106, 2016.
, “Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.
, “Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.
, “Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.
, “Different Expression Patterns of Amyloid-β Protein Precursor Secretases in Human and Mouse Hippocampal Neurons: A Potential Contribution to Species Differences in Neuronal Susceptibility to Amyloid-β Pathogenesis.”, J Alzheimers Dis, vol. 51, no. 1, pp. 179-95, 2016.
, “Different Expression Patterns of Amyloid-β Protein Precursor Secretases in Human and Mouse Hippocampal Neurons: A Potential Contribution to Species Differences in Neuronal Susceptibility to Amyloid-β Pathogenesis.”, J Alzheimers Dis, vol. 51, no. 1, pp. 179-95, 2016.
, “Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.”, J Alzheimers Dis, vol. 51, no. 3, pp. 905-13, 2016.
, “Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1033-43, 2016.
, “Differential Membrane Toxicity of Amyloid-β Fragments by Pore Forming Mechanisms.”, J Alzheimers Dis, vol. 51, no. 3, pp. 689-99, 2016.
, “Differential Membrane Toxicity of Amyloid-β Fragments by Pore Forming Mechanisms.”, J Alzheimers Dis, vol. 51, no. 3, pp. 689-99, 2016.
, “Differential Membrane Toxicity of Amyloid-β Fragments by Pore Forming Mechanisms.”, J Alzheimers Dis, vol. 51, no. 3, pp. 689-99, 2016.
,